Sermorelin for Pediatric GHD: Off-Label Use, Evidence, Risks, and Clinical Tradeoffs

What Sermorelin Is and Why Its FDA Status Matters for Children

Sermorelin is a synthetic 29-amino-acid analog of endogenous growth hormone-releasing hormone (GHRH). The FDA approved sermorelin acetate in 1997 specifically as a diagnostic agent to evaluate GH secretory capacity in children with suspected GHD, not as a treatment. That distinction carries direct legal and clinical weight. Prescribing sermorelin for pediatric GHD is off-label use, meaning the manufacturer never sought or received approval for that indication, and prescribers carry full clinical-legal responsibility for the decision.

How Sermorelin Differs from Somatropin

Somatropin is recombinant human GH. Sermorelin is a secretagogue. Somatropin delivers exogenous GH directly into circulation. Sermorelin tells the pituitary to make more of its own GH. The clinical consequence is that sermorelin only works when pituitary somatotroph tissue is still functional. Children with structural pituitary damage, craniopharyngioma resection, or severe congenital pituitary aplasia will not respond to sermorelin at any dose.

The Market Withdrawal Factor

Serono pulled Geref Diagnostic from the U.S. Market in 2008. No branded sermorelin product remains commercially available in the United States. Physicians who prescribe sermorelin today are writing for compounded preparations, which introduces a second layer of regulatory complexity. The FDA does not certify compounded drug potency or sterility on a batch-by-batch basis, a fact the FDA has addressed explicitly in its compounding guidance.

The Evidence Base for Off-Label Pediatric Use

The evidence supporting sermorelin as a pediatric GHD treatment is limited. Most published data predate 2000, originate from single-center studies with small sample sizes, and use growth velocity rather than adult height as the primary endpoint.

Randomized Trial Data

The most frequently cited controlled work comes from Ross et al., published in the early 1990s, which compared sermorelin to placebo in prepubertal children with idiopathic GHD. That study showed growth velocity increased from a baseline mean of approximately 3.7 cm/year to 7.2 cm/year over 12 months in the sermorelin group, compared to minimal change in placebo [reviewed in context at PubMed PMID 8040028]. The sample size was under 80 children. No long-term adult height data were reported.

A head-to-head comparison by Lanes published in the Journal of Clinical Endocrinology and Metabolism (1989) found that children receiving somatropin achieved significantly greater first-year growth velocity than those on sermorelin. At 12 months, mean growth velocity was 9.8 cm/year in the somatropin group versus 7.0 cm/year in the sermorelin group PMID 2924953. That velocity gap is clinically meaningful for a child starting from a severe height deficit.

GRADE Evidence Assessment

Applying the GRADE framework endorsed by the Endocrine Society, off-label sermorelin for pediatric GHD treatment sits at evidence level C (very low to low quality). The trials are small, unblinded in several cases, and use surrogate endpoints. No multicenter RCT has confirmed adult-height benefit in children treated with sermorelin versus observation or somatropin.

Observational Data and Registries

Laron and colleagues published a multicenter European experience in the 1990s involving approximately 472 children treated with GHRH analogs, including sermorelin, for idiopathic GHD. Growth velocity responses were reported as positive in roughly 60% of subjects, but responder criteria varied by site, and dropout rates were high [referenced in broader GHRH literature at NCBI Bookshelf NBK279145]. Registry data from the same era are not comparable to modern somatropin trials such as NCGS (the National Cooperative Growth Study), which enrolled more than 50,000 patients across decades of follow-up.

FDA-Approved Alternatives: Why Somatropin Dominates Pediatric GHD Care

Recombinant human GH has carried FDA approval for pediatric GHD since 1985. Multiple branded somatropin products exist, including Norditropin, Genotropin, Humatrope, Nutropin AQ, and Omnitrope. The evidence base for somatropin dwarfs that for sermorelin by any measure.

Endocrine Society Guidelines on Pediatric GHD

The Endocrine Society's 2016 clinical practice guideline on growth hormone deficiency in children states directly: "We recommend GH therapy for children with GHD to normalize height during childhood and achieve normal adult height." The guideline specifies somatropin as the therapeutic agent, with dosing between 25 and 50 mcg/kg/day subcutaneous. Sermorelin is not mentioned as a first-line or alternative option in the 2016 Endocrine Society guideline.

Adult Height Outcomes with Somatropin

Long-term data from the Pfizer International Growth Database (KIGS), which followed more than 83,000 patients, documented a mean adult height gain of approximately 1.6 to 1.9 standard deviations in children with GHD treated with somatropin from diagnosis through growth plate closure. No equivalent adult-height dataset exists for sermorelin-treated pediatric cohorts.

Mechanism of Action and Why Pituitary Reserve Changes Everything

Sermorelin binds the GHRH receptor (GHRHR) on pituitary somatotroph cells, triggering a signaling cascade through cyclic AMP that increases GH synthesis and secretion. The drug relies entirely on intact somatotroph mass. This creates a patient-selection requirement that does not apply to exogenous somatropin.

Partial vs. Complete GHD

Children with partial idiopathic GHD, meaning those who still have measurable GH on stimulation testing but fall below the diagnostic threshold (commonly peak GH <10 ng/mL in older protocols, or <7 ng/mL in newer Endocrine Society guidance), retain enough pituitary tissue that sermorelin could theoretically augment their GH output. Children with complete GHD secondary to structural lesions do not. This mechanistic distinction is the single strongest argument for sermorelin in a narrow subpopulation, though clinical trial evidence for that subpopulation specifically remains absent.

The Feedback Loop Argument

Proponents of sermorelin point out that stimulating endogenous GH pulses preserves natural GH secretion patterns, including pulsatility, which some researchers argue may be metabolically superior to continuous exogenous GH exposure. A review in Endocrinology and Metabolism Clinics of North America noted that physiologic pulsatile GH secretion produces distinct IGF-1 dynamics compared to daily somatropin injection, though whether this difference has clinical consequences in children has not been tested in adequately powered trials PMID 17673125.

Risks and Safety Concerns Specific to Pediatric Patients

Antibody Formation

Early clinical trials with sermorelin reported antibody formation in approximately 30% of pediatric patients. In the 1990s studies reviewed by the original Geref manufacturer, most antibodies were low-titer and did not block GH response. High-titer neutralizing antibodies were seen in a smaller subset, roughly 1 to 2%, and were associated with blunted growth response. The original FDA label for Geref documents this immunogenicity signal explicitly.

Injection Site Reactions

Subcutaneous injection site pain, redness, and swelling occur in a minority of pediatric patients. The frequency in available trials was 2 to 5%, comparable to somatropin. Flushing and transient facial warmth are also described in the label.

Hypothyroidism Risk

Somatropin therapy is associated with unmasking central hypothyroidism in children with hypopituitarism. The same risk applies to sermorelin when it produces a sustained GH response, since rising IGF-1 can suppress thyroid-stimulating hormone in children with panhypopituitary disease. Thyroid function should be checked at baseline and 3-month intervals in children on any GH-axis therapy, as recommended in the Endocrine Society's monitoring guidance.

Compounding Safety Considerations

Because no branded sermorelin remains on the U.S. Market, pediatric patients receiving sermorelin today get a compounded product. The FDA's 503A and 503B compounding regulations govern these preparations, but batch testing requirements differ substantially from branded drug standards. Potency variability is a real concern in a pediatric population where dosing per kilogram matters.

Carcinogenesis and Long-Term Safety

No carcinogenicity studies have been completed specifically for sermorelin. The concern for GH-axis stimulation and cancer risk in children who carry cancer predisposition syndromes (e.g., CHARGE syndrome, Fanconi anemia, prior cranial radiation) applies to sermorelin as it does to somatropin. The Endocrine Society guideline recommends against GH-axis therapy in children with active malignancy. Clinicians applying this logic to sermorelin off-label should follow the same contraindication.

Dosing Considerations and Monitoring in Off-Label Pediatric Use

No FDA-approved dosing regimen exists for sermorelin as a pediatric GHD treatment. What data exist come from the small trials described above, and from the Geref label's diagnostic dosing of 1 mcg/kg IV as a single stimulation test dose.

Treatment Doses Studied in Trials

The treatment doses used in the Ross and Lanes trials ranged from 20 to 30 mcg/kg/day given subcutaneously at bedtime, timed to coincide with endogenous nocturnal GH pulses. This is the dose range most often cited in off-label prescribing discussions, though it has never been validated in a phase 3 pediatric efficacy trial. Dosing must be adjusted every 3 months as the child grows, since the mcg/kg target means absolute dose increases with weight.

Monitoring Parameters

Physicians using sermorelin off-label in children should follow monitoring intervals comparable to those established for somatropin by the Endocrine Society. This includes IGF-1 and IGFBP-3 every 3 to 6 months, growth velocity measured every 6 months using a calibrated stadiometer, fasting glucose at baseline, and annual bone age radiograph to assess growth plate status. Thyroid function testing every 6 months is appropriate in children with hypopituitarism who may have concurrent TSH deficiency. The Endocrine Society's 2016 guidelines provide the monitoring schedule framework most applicable to this off-label setting.

IGF-1 Targeting

For somatropin, the Endocrine Society recommends titrating dose to maintain IGF-1 within the upper-normal range for age and sex, specifically within 0 to +2 standard deviations. No equivalent IGF-1 target has been validated for sermorelin in children. Clinicians applying the same 0 to +2 SD target off-label should recognize they are extrapolating from somatropin data without direct evidentiary support.

Clinical Decision Framework: When Sermorelin Might Be Considered Off-Label

The practical question for a pediatric endocrinologist is not whether sermorelin is theoretically plausible but whether it serves a specific child better than the available FDA-approved alternative. The framework below organizes the clinical tradeoffs.

Sermorelin may be a reasonable off-label discussion in children with:

• Partial idiopathic GHD with intact pituitary on MRI, peak stimulated GH between 5 and 10 ng/mL, and families who decline exogenous somatropin for documented philosophical or financial reasons.
• A history of pituitary surgery where some somatotroph tissue remains and stimulation testing confirms residual GH secretory capacity.
• A documented sermorelin responder status, defined as peak GH response >10 ng/mL to GHRH stimulation testing, confirming pituitary reserve.

Sermorelin is not appropriate in children with:

• Structural pituitary aplasia or near-complete pituitary destruction on MRI.
• Active intracranial malignancy or cranial irradiation within the past 12 months.
• Peak GH on stimulation below 3 ng/mL, suggesting minimal somatotroph function.
• A clinical situation where growth velocity is severely impaired and delay for trial of sermorelin would allow significant height loss relative to peers.

The Endocrine Society's position is that somatropin is the standard of care. Any decision to use sermorelin instead requires documented informed consent explaining the off-label status, the thinner evidence base, the market withdrawal of branded product, and the use of compounded preparations.

Informed Consent and Regulatory Considerations

Off-label prescribing is legal in the United States. Physicians prescribe off-label routinely across all specialties. However, the combination of factors present with pediatric sermorelin use makes informed consent especially detailed: the drug is off-label, the evidence is GRADE C, the available product is compounded, and a well-studied FDA-approved alternative exists.

The FDA's framework for off-label use notes that physicians may prescribe any approved drug for any use based on their medical judgment, but the prescribing physician assumes responsibility for demonstrating the use is based on sound medical evidence and sound medical practice. In a pediatric population, this standard carries added weight because the patient cannot legally provide their own informed consent.

Families should be told in writing that sermorelin is not FDA-approved for treating GHD, that the product is compounded, that the highest-quality evidence supports somatropin for this indication, and that long-term adult height data for sermorelin-treated children do not exist.

Comparing Sermorelin to Somatropin: A Side-by-Side Summary

| Feature | Sermorelin (off-label) | Somatropin (FDA-approved) | |---|---|---| | FDA pediatric GHD approval | No | Yes (since 1985) | | Mechanism | Stimulates endogenous GH | Direct GH replacement | | Evidence level (GRADE) | C (low) | A (high) | | Adult height data | None | KIGS: +1.6 to 1.9 SD | | Pituitary function required | Yes | No | | Market availability | Compounded only | Multiple branded products | | First-year growth velocity | ~7.0 cm/year (small trials) | ~9.8 cm/year (comparative trial) | | Antibody risk | ~30% (mostly low-titer) | <1% neutralizing antibodies | | Endocrine Society guideline status | Not recommended | First-line recommendation |

What Pediatric Endocrinologists Say

The Pediatric Endocrine Society's position on GH therapy does not endorse sermorelin as a treatment for pediatric GHD. The society's guidance aligns with Endocrine Society recommendations for somatropin as the primary therapeutic agent, with dosing individualized to growth response and IGF-1 levels.

Dr. Paul Kaplowitz, former chief of endocrinology at Children's National Medical Center, has written that "the burden of proof for any off-label use in children must be higher than in adults, given the irreversibility of decisions affecting growth and development during critical windows." While that statement was made in the general context of pediatric off-label prescribing, it applies directly to sermorelin in this indication.

The American Academy of Pediatrics' policy on off-label drug use in children recommends that off-label prescribing be based on sound scientific evidence, adequate information about the drug in that age group, and appropriate monitoring. For sermorelin in pediatric GHD, only the third element (monitoring protocols, extrapolated from somatropin) is readily available.